Skip to main
PCVX

Vaxcyte (PCVX) Stock Forecast & Price Target

Vaxcyte (PCVX) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Vaxcyte is well-positioned in the crowded vaccine market with its high-fidelity vaccines designed to protect against bacterial diseases. With a product pipeline that shows promising results and targets a wide range of age groups, Vaxcyte is set to capture a significant portion of the expanding vaccine market. With a diverse and strong product portfolio, favorable market conditions, and upcoming key data readouts, Vaxcyte's stock has a positive outlook for investors.

Bears say

Vaxcyte is facing intense competition in the market for pneumococcal vaccines, and while early data from their lead candidate VAX-24 is promising, it has yet to be shown if it can effectively differentiate itself from established products. Additionally, there are significant risks associated with vaccine development, including potential safety and efficacy concerns, which may limit the commercial potential of Vaxcyte's products. Finally, the company's resources are also limited in comparison to its competitors, which may make it challenging to successfully bring its products to market and build a commercial infrastructure.

Vaxcyte (PCVX) has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vaxcyte (PCVX) Forecast

Analysts have given Vaxcyte (PCVX) a Buy based on their latest research and market trends.

According to 4 analysts, Vaxcyte (PCVX) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vaxcyte (PCVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.